Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01101269 · ClinicalTrials.gov registry record · NA
Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease
A NA study, sponsored by University of Virginia.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT01101269 is a NA study that was terminated before completion, run by University of Virginia. The registered enrollment target is 6 participants.
The verdict
NCT01101269, a NA study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the effect of a blood pressure medication, Lisinopril, or similar drugs in that class, on the flow of blood to the kidneys. In this study, we will compare blood flow to the kidneys in healthy people that do not have diabetes or kidney disease with people that have diabetes and evidence of kidney disease.
Interventions
- DRUG Lisinopril
- DRUG ACEI or ARB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01101269
The ClinicalTrials.gov registry entry for NCT01101269 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lisinopril is the first listed.
NCT01101269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01101269 about?
NCT01101269 is a clinical study titled "Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease". The purpose of the study is to investigate the effect of a blood pressure medication, Lisinopril, or similar drugs in that class, on the flow of blood to the kidneys. In this study, we will compare blood flow to the kidneys in healthy people that do not have diabetes or kidney disease with people th...
What is the current status of trial NCT01101269?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2010-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01101269?
The interventions under investigation include: Lisinopril (DRUG), ACEI or ARB (DRUG).
Who is sponsoring clinical trial NCT01101269?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.